IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishCarcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.
Bassi, P., Volpe, A., D'agostino, D., Palermo, G., Renier, D., Franchini, S., Rosato, A., Racioppi, M., Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study, <<THE JOURNAL OF UROLOGY>>, 2011; 185 (2): 445-449. [doi:10.1016/j.juro.2010.09.073] [http://hdl.handle.net/10807/2113]
| Autori: | |
| Titolo: | Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.juro.2010.09.073 |
| Data di pubblicazione: | 2011 |
| Abstract: | Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin. |
| Lingua: | Inglese |
| Rivista: | |
| Citazione: | Bassi, P., Volpe, A., D'agostino, D., Palermo, G., Renier, D., Franchini, S., Rosato, A., Racioppi, M., Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study, <<THE JOURNAL OF UROLOGY>>, 2011; 185 (2): 445-449. [doi:10.1016/j.juro.2010.09.073] [http://hdl.handle.net/10807/2113] |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Copyright © 2020